Your browser is no longer supported. Please, upgrade your browser.
Settings
ATNX Athenex, Inc. daily Stock Chart
ATNX [NASD]
Athenex, Inc.
Index- P/E- EPS (ttm)-1.40 Insider Own7.10% Shs Outstand81.54M Perf Week-0.78%
Market Cap950.34M Forward P/E- EPS next Y-1.11 Insider Trans16.21% Shs Float51.52M Perf Month25.61%
Income-107.90M PEG- EPS next Q-0.30 Inst Own58.30% Short Float17.79% Perf Quarter-13.33%
Sales122.90M P/S7.73 EPS this Y8.10% Inst Trans7.57% Short Ratio13.19 Perf Half Y-27.52%
Book/sh2.10 P/B5.42 EPS next Y36.70% ROA-35.50% Target Price- Perf Year-21.73%
Cash/sh1.36 P/C8.36 EPS next 5Y- ROE-63.10% 52W Range5.63 - 21.11 Perf YTD-25.47%
Dividend- P/FCF- EPS past 5Y-39.10% ROI-49.90% 52W High-46.09% Beta-
Dividend %- Quick Ratio2.40 Sales past 5Y142.30% Gross Margin43.60% 52W Low102.13% ATR0.69
Employees574 Current Ratio2.80 Sales Q/Q85.40% Oper. Margin-82.10% RSI (14)61.32 Volatility6.88% 6.28%
OptionableYes Debt/Eq0.31 EPS Q/Q54.70% Profit Margin-87.90% Rel Volume0.62 Prev Close11.87
ShortableYes LT Debt/Eq0.31 EarningsMay 07 BMO Payout- Avg Volume694.88K Price11.38
Recom1.70 SMA206.34% SMA5022.44% SMA200-8.23% Volume433,079 Change-4.13%
Jun-25-19Reiterated RBC Capital Mkts Outperform $29 → $31
May-02-19Initiated Oppenheimer Outperform $20
Mar-29-19Initiated SunTrust Buy $20
Nov-15-18Upgrade JP Morgan Neutral → Overweight
Oct-25-18Initiated Ladenburg Thalmann Buy $27
Mar-06-18Initiated Needham Buy $30
Oct-18-17Initiated JP Morgan Neutral $22.20
Sep-18-17Initiated Credit Suisse Outperform $25
Sep-15-17Initiated RBC Capital Mkts Outperform $35
Jun-03-20 04:50PM  
Jun-02-20 06:12AM  
May-29-20 08:00AM  
May-27-20 12:40PM  
08:40AM  
May-25-20 03:45PM  
May-19-20 09:05AM  
May-12-20 12:00PM  
11:29AM  
May-09-20 01:31PM  
May-08-20 12:41PM  
May-07-20 06:47PM  
09:47AM  
08:45AM  
07:00AM  
Apr-30-20 12:34PM  
Apr-29-20 01:54PM  
Apr-23-20 08:00AM  
Apr-09-20 07:00AM  
Mar-13-20 08:10AM  
Mar-11-20 07:06AM  
Mar-10-20 07:05PM  
Mar-09-20 07:00AM  
Mar-06-20 12:00PM  
Mar-02-20 10:19AM  
Feb-27-20 10:15AM  
07:00AM  
06:00AM  
Feb-25-20 08:00AM  
Feb-20-20 12:31PM  
Feb-06-20 07:00AM  
Feb-03-20 05:01PM  
Jan-16-20 09:46AM  
05:58AM  
Jan-08-20 01:51PM  
Dec-28-19 05:17PM  
Dec-27-19 02:57PM  
Dec-22-19 01:52PM  
Dec-16-19 07:00AM  
Dec-13-19 09:46AM  
09:31AM  
08:30AM  
Dec-11-19 07:00AM  
Dec-09-19 08:10PM  
Dec-05-19 08:00AM  
Dec-02-19 05:00AM  
Nov-21-19 08:42AM  
Nov-19-19 09:05AM  
Nov-18-19 03:29AM  
Nov-07-19 08:35AM  
07:00AM  
Oct-31-19 10:34AM  
Oct-30-19 07:00AM  
Oct-28-19 03:30AM  
Oct-26-19 12:33PM  
Oct-24-19 07:00AM  
07:00AM  
Oct-21-19 04:46PM  
11:29AM  
Oct-18-19 06:49AM  
Oct-10-19 10:34PM  
Oct-07-19 12:14PM  
Sep-30-19 11:44AM  
Sep-23-19 07:00AM  
07:00AM  
07:00AM  
Sep-22-19 04:44PM  
Sep-13-19 05:15AM  
Sep-12-19 07:15AM  
Sep-11-19 07:00AM  
Sep-04-19 07:00AM  
Aug-27-19 12:00PM  
Aug-23-19 06:15PM  
Aug-17-19 06:40PM  
Aug-13-19 06:04AM  
Aug-07-19 07:23PM  
04:17PM  
03:46PM  
07:35AM  
06:00AM  
06:00AM  
05:58AM  
Aug-02-19 08:00AM  
Jul-31-19 10:36AM  
Jul-29-19 08:00AM  
Jul-09-19 11:23AM  
Jun-28-19 07:00AM  
Jun-27-19 08:00AM  
Jun-24-19 07:00AM  
Jun-23-19 07:30AM  
Jun-10-19 06:06PM  
05:30PM  
Jun-06-19 07:00AM  
07:00AM  
May-30-19 07:00AM  
May-09-19 03:23PM  
09:07AM  
May-06-19 04:31PM  
10:20AM  
08:00AM  
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and oral eribulin, an intravenous anticancer drug to treat certain patients with breast cancer and advanced liposarcoma. In addition, the company offers Src Kinase product candidates comprising KX2-391 ointments for actinic keratosis, skin cancers, and psoriasis; KX-01 oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and Pegtomarginase, an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 27Buy7.881,0007,8803,112,959Mar 27 04:30 PM
Sze RandollChief Financial OfficerMar 27Buy8.191,0008,1905,000Mar 27 04:14 PM
Fok MansonDirectorMar 25Buy7.2550,000362,5001,969,609Mar 26 05:07 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 23Buy6.641,0006,6403,111,959Mar 23 04:30 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 20Buy6.851,0006,8503,110,959Mar 20 04:09 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 19Buy6.602,00013,2003,109,959Mar 19 04:14 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 18Buy5.782,00011,5603,107,959Mar 18 04:11 PM
Kwan RudolfEVP, Chief Medical OfficerMar 18Buy5.904,00023,584141,048Mar 19 04:19 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 17Buy6.902,00013,8003,105,959Mar 17 04:42 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 16Buy7.612,00015,2203,103,959Mar 16 04:11 PM
TSANG Benson Kwan HungDirectorMar 13Buy8.395,00041,95010,000Mar 16 06:55 AM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 12Buy8.354,00033,3963,099,959Mar 12 04:11 PM
YORDON JEFFREYSee RemarksMar 12Buy8.1410,00081,430218,926Mar 12 04:15 PM
Kwan RudolfEVP, Chief Medical OfficerMar 12Buy8.192,00016,380137,048Mar 13 04:16 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 12Buy8.122,00016,2403,101,959Mar 13 04:13 PM
TSANG Benson Kwan HungDirectorMar 12Buy8.345,00041,7005,000Mar 13 05:23 PM
Fok MansonDirectorMar 11Buy10.2850,000513,8501,919,609Mar 11 04:21 PM
Kwan RudolfEVP, Chief Medical OfficerMar 09Buy9.792,00019,573135,048Mar 10 04:30 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 24Buy14.3973,6981,060,51411,532,467Dec 27 04:00 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 23Buy14.30153,2372,191,28911,458,769Dec 26 06:04 AM
PERCEPTIVE ADVISORS LLC10% OwnerDec 20Buy14.14189,3222,677,01311,305,532Dec 26 06:04 AM
PERCEPTIVE ADVISORS LLC10% OwnerDec 19Buy13.78263,7433,635,48411,116,210Dec 26 06:04 AM
WU JINNDirectorDec 18Option Exercise4.5520,00091,000371,208Dec 19 04:09 PM
Sze RandollChief Financial OfficerDec 17Buy13.251,00013,2504,000Dec 17 04:11 PM
WU JINNDirectorDec 16Option Exercise4.5530,000136,500351,208Dec 18 04:19 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardDec 16Option Exercise4.5515,00068,2503,095,959Dec 17 04:08 PM
Fok MansonDirectorNov 07Buy11.6750,000583,5001,869,609Nov 12 04:06 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardOct 22Option Exercise4.555,00022,7503,080,959Oct 23 08:03 AM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardOct 21Option Exercise4.5510,00045,5003,075,959Oct 22 04:40 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardOct 17Option Exercise4.5510,00045,5003,065,959Oct 18 04:05 PM
Sze RandollChief Financial OfficerOct 17Buy10.991,00010,9903,000Oct 17 04:11 PM
PERCEPTIVE ADVISORS LLC10% OwnerOct 17Buy10.9350,000546,50010,852,467Oct 21 06:00 PM
PERCEPTIVE ADVISORS LLC10% OwnerOct 16Buy10.2967,222691,71410,802,467Oct 18 06:00 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardOct 16Buy10.166,00060,9603,055,959Oct 16 04:30 PM
Sze RandollChief Financial OfficerSep 30Buy12.621,00012,6202,000Sep 30 04:13 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 27Buy12.853,00038,5503,049,959Sep 30 04:08 PM
Kwan RudolfEVP, Chief Medical OfficerSep 25Option Exercise4.5524,000109,200132,106Sep 25 04:40 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 23Buy13.865,00069,3003,046,959Sep 23 04:08 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 16Buy13.5830,000407,40010,735,245Sep 18 05:30 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 16Buy13.575,00067,8503,041,959Sep 16 04:25 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 13Buy14.2756,416805,05610,705,245Sep 16 07:31 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 12Buy14.0513,584190,85510,648,829Sep 16 07:31 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardAug 23Buy14.985,00074,9003,036,959Aug 23 04:08 PM
PERCEPTIVE ADVISORS LLC10% OwnerAug 16Buy14.9620,000299,20010,635,245Aug 16 05:31 PM
Kwan RudolfEVP, Chief Medical OfficerAug 15Buy14.851,00014,850108,106Aug 16 04:13 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardAug 15Buy14.9010,000149,0003,031,959Aug 15 04:14 PM
PERCEPTIVE ADVISORS LLC10% OwnerAug 15Buy15.0030,000450,00010,615,245Aug 16 05:31 PM
PERCEPTIVE ADVISORS LLC10% OwnerAug 08Buy15.7630,000472,80010,585,245Aug 09 05:55 PM
PERCEPTIVE ADVISORS LLC10% OwnerAug 07Buy14.43733,12710,576,25110,555,245Aug 09 05:55 PM
Davis Stephanie ADirectorJun 26Buy18.0010,000180,00010,000Jun 27 08:15 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 25Buy17.891,49526,7469,822,118Aug 09 05:55 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 24Buy17.9020,786372,0699,820,623Aug 09 05:55 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 21Buy17.8523,073411,8539,799,837Aug 09 05:55 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 18Buy17.7350,742899,6569,776,764Jun 20 08:00 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 17Buy17.94130,0002,332,2009,726,022Jun 19 08:00 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 14Buy17.69324,2905,736,6909,596,022Jun 18 08:00 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 13Buy17.0575,7101,290,8569,271,732Jun 17 08:00 PM
Kanfer JordanDirectorJun 06Buy15.012,50037,5254,184Jun 07 04:16 PM